New drug trial aims to stop dangerous bleeding in heart patients
NCT ID NCT07479056
Summary
This study is testing a new stomach-protecting drug called Fexuprazan. It aims to prevent dangerous stomach bleeding in people who have had a heart stent and must take strong blood thinners. Researchers will compare Fexuprazan to standard medications in 400 high-risk patients to see which is better at preventing bleeding complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DISEASES OF THE CIRCULATORY SYSTEM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
RECRUITINGSeoul, Eunpyeong-gu, 03312, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.